Abstract
Summary
This study examined whether markers of bone turnover differ between individuals with and without diabetes. Bone markers showed heterogeneity between studies and were discrepant for markers of bone creation and markers of bone degradation. Bone markers may be of lesser value in diabetes due to heterogeneity.
Introduction
The aim of this meta-analysis was to compare existing literature regarding changes in bone markers among diabetics compared to healthy controls. To exclude that blood glucose levels among diabetes patients could influence the assays used for determining bone turnover markers, a methodological study was performed.
Methods
Medline at Pubmed Embase, Cinahl, Svemed+, Cochrane library, and Bibliotek.dk was searched in August 2012. The studies should examine biochemical bone turnover among diabetes patients in comparison to controls in an observational design. In the methodological study, fasting blood samples were drawn from two individuals. Glucose was added to the blood samples in different concentrations and OC, CTX, and procollagen type 1 amino terminal propeptide were measured after 0, 1, 2, and 3 h.
Results
Twenty-two papers fulfilled the criteria for the meta-analysis. From the pooled data in the meta-analysis, the bone markers osteocalcin (OC) (−1.15 ng/ml [−1.78,-0.52]) and C-terminal cross-linked telopeptide (CTX) (−0.14 ng/ml [−0.22, −0.05]) were significantly lower among diabetes patients than non-diabetes patients, however other markers did not differ. All markers displayed very high heterogeneity by I2 statistics. In the methodological study, the addition of glucose did not significantly change the bone markers neither by level of glucose nor with increasing incubation time.
Conclusion
The dissociative pattern of biochemical bone markers of bone formation and bone resorption present in diabetes patients is thus not caused by glucose per se but may be modulated by unknown factors associated with diabetes mellitus.
Similar content being viewed by others
References
Garnero P (2009) Bone markers in osteoporosis. Curr Osteoporos Rep 7:84–90
Delmas PD (1991) What do we know about biochemical bone markers? Baillieres Clin Obstet Gynaecol 5:817–830
Starup-Linde J (2013) Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol (Lausanne) 4:21
Vestergaard P, Rejnmark L, Mosekilde L (2009) Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 84:45–55
Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444
Szulc P, Delmas PD (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19:1683–1704
Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A (2003) Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 88:4867–4873
McNair P, Madsbad S, Christensen MS, Christiansen C, Faber OK, Binder C, Transbol I (1979) Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) 90:463–472
Raskin P, Stevenson MR, Barilla DE, Pak CY (1978) The hypercalciuria of diabetes mellitus: its amelioration with insulin. Clin Endocrinol (Oxf) 9:329–335
Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, Abboud-Werner SL (2008) High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42:1122–1130
Hamada Y, Fujii H, Fukagawa M (2009) Role of oxidative stress in diabetic bone disorder. Bone 45(Suppl 1):S35–S38
Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT (2007) Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40:345–353
Saito M, Marumo K (2013) Bone quality in diabetes. Front Endocrinol (Lausanne) 4:72
Manolagas SC, Almeida M (2007) Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 21:2605–2614
Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97:1737–1744
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
Munoz-Torres M, Jodar E, Escobar-Jimenez F, Lopez-Ibarra PJ, Luna JD (1996) Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 58:316–319
Christensen JO, Svendsen OL (1999) Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. Osteoporos Int 10:307–311
Pedrazzoni M, Ciotti G, Pioli G, Girasole G, Davoli L, Palummeri E, Passeri M (1989) Osteocalcin levels in diabetic subjects. Calcif Tissue Int 45:331–336
Danielson KK, Elliott ME, Lecaire T, Binkley N, Palta M (2009) Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 20:923–933
Neumann T, Samann A, Lodes S, Kastner B, Franke S, Kiehntopf M, Hemmelmann C, Lehmann T, Muller UA, Hein G, Wolf G (2011) Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med 28:872–875
Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T (2008) Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 31:1729–1735
Hampson G, Evans C, Petitt RJ, Evans WD, Woodhead SJ, Peters JR, Ralston SH (1998) Bone mineral density, collagen type 1 (alpha) 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 41:1314–1320
Shu A, Yin MT, Stein E, Cremers S, Dworakowski E, Ives R, Rubin MR (2012) Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int 23:635–641
Zhou Y, Li Y, Zhang D, Wang J, Yang H (2010) Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes. Diabetes Res Clin Pract 90:261–269
Gerdhem P, Isaksson A, Akesson K, Obrant KJ (2005) Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16:1506–1512
Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A (2006) Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 91:3355–3363
Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Derouiche EM, Ghafir D, El Maghraoui A (2005) Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol 24:493–496
Aboelasrar M, Farid S, El Maraghy M, Mohamedeen A (2010) Serum osteocalcin, zinc nutritive status and bone turnover in children and adolescents with type1 diabetes mellitus. Pediatr Diabetes 11:50
Abd El Dayem SM, El-Shehaby AM, Abd El Gafar A, Fawzy A, Salama H (2011) Bone density, body composition, and markers of bone remodeling in type 1 diabetic patients. Scand J Clin Lab Invest 71:387–393
Hamed EA, Faddan NH, Elhafeez HA, Sayed D (2011) Parathormone-25(OH)-vitamin D axis and bone status in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 12:536–546
Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A (2002) The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 58:266–272
Leon M, Larrodera L, Lledo G, Hawkins F (1989) Study of bone loss in diabetes mellitus type 1. Diabetes Res Clin Pract 6:237–242
Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, Falcini F, Chiarelli F (2005) Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 153:879–885
Khalil N, Sutton-Tyrrell K, Strotmeyer ES, Greendale GA, Vuga M, Selzer F, Crandall CJ, Cauley JA (2011) Menopausal bone changes and incident fractures in diabetic women: a cohort study. Osteoporos Int 22:1367–1376
Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T (2012) Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 97:1277–1284
Bhattoa HP, Onyeka U, Kalina E, Balogh A, Paragh G, Antal-Szalmas P, Kaplar M (2013) Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50 years of age with type 2 diabetes mellitus: a case–control study. Clin Rheumatol 32(8):1–7
Herrmann M, Seibel MJ (2008) The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta 393:57–75
Orwoll ES, Deftos LJ (1990) Serum osteocalcin (BGP) levels in normal men: a longitudinal evaluation reveals an age-associated increase. J Bone Miner Res 5:259–262
Tsai KS, Chen JS, Hwang KM, Chieng PU, Su CT (1991) Age-related changes in vitamin D metabolites, osteocalcin, alkaline phosphatase and parathyrin in normal Chinese women in Taipei. J Formos Med Assoc 90:1033–1037
Liu G, Peacock M (1998) Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calcif Tissue Int 62:286–289
Vanderschueren D, Gevers G, Raymaekers G, Devos P, Dequeker J (1990) Sex- and age-related changes in bone and serum osteocalcin. Calcif Tissue Int 46:179–182
Seibel MJ, Lang M, Geilenkeuser WJ (2001) Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47:1443–1450
Whitham KM, Milford-Ward A (2000) External quality assessment of bone metabolism marker assays. Initial experiences in a UK NEQAS programme. Clin Chem Lab Med 38:1121–1124
Meier C, Seibel MJ, Kraenzlin ME (2009) Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24:386–388
Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA (2011) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49:1271–1274
Okuno S, Ishimura E, Tsuboniwa N, Norimine K, Yamakawa K, Yamakawa T, Shoji S, Mori K, Nishizawa Y, Inaba M (2012) Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients. Osteoporos Int 24:1–8
Acknowledgments
The authors would like to acknowledge the assistance of research librarian Ms. Edith Clausen, Department of Endocrinology and Internal Medicine, Aarhus University Hospital.
Funding
The authors have received no funding for this study.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 53 kb)
Rights and permissions
About this article
Cite this article
Starup-Linde, J., Eriksen, S.A., Lykkeboe, S. et al. Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int 25, 1697–1708 (2014). https://doi.org/10.1007/s00198-014-2676-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-014-2676-7